Valeant Pharmaceuticals International Inc. is preparing to namePaul Herendeen, an executive at veterinary drugmaker Zoetis Inc.,as its new chief financial officer, according to people familiarwith the matter.
The announcement will mark the latest management change at theembattled drugmaker, which replaced CEO Michael Pearson earlierthis year. Herendeen has been working as CFO at Zoetis since September 2014.Before that, he was CFO of specialty drugmaker Warner Chilcott Plc,according to Zoetis's website.
He replaces Robert Rosiello, who will remain at Valeant in anexecutive role involving corporate development and strategy,according to the people who spoke on condition of anonymity becausethe matter was still private. At Zoetis, Herendeen will be replacedby Glenn David, the company's senior vice president of financeoperations.
Continue Reading for Free
Register and gain access to:
- Thought leadership on regulatory changes, economic trends, corporate success stories, and tactical solutions for treasurers, CFOs, risk managers, controllers, and other finance professionals
- Informative weekly newsletter featuring news, analysis, real-world cas studies, and other critical content
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the employee benefits and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
*May exclude premium content
Already have an account?
Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
